J.P. Morgan analyst Eric Joseph maintained a Hold rating on Atea Pharmaceuticals (AVIR – Research Report) today and set a price target of $8.00. The company’s shares opened today at $3.65.
Joseph covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Pliant Therapeutics, and Enanta Pharmaceuticals. According to TipRanks, Joseph has an average return of 9.1% and a 53.85% success rate on recommended stocks.
Currently, the analyst consensus on Atea Pharmaceuticals is a Moderate Sell with an average price target of $5.33, representing a 46.03% upside. In a report released on March 1, SVB Securities also reiterated a Hold rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $9.79 and a one-year low of $3.15. Currently, Atea Pharmaceuticals has an average volume of 458.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company’s medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.
Read More on AVIR:
- Atea announces presentation of Phase 1 data of bemnifosbuvir at ICAR 2023
- New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research
- Atea Pharmaceuticals announces upcoming presentations at ICAR
- New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
- Atea Pharmaceuticals reports Q4 EPS (41c), consensus (45c)
